Aug 17, 2026
EyePoint drug fails pivotal trial, company loses nearly $1 billion in market value
Boston-area biotechnology company EyePoint's main drug candidate failed to hit the central goal of its pivotal LUGANO trial for vision treatment, causing shares to plummet and wiping out nearly a billion dollars in market value.
2 sources
00